Key result
Vitamin D supplementation reduces LDL-C by ~0.14 mmol/L alongside modest blood pressure and glucose improvements.
Why the study?
Does oral vitamin D supplementation improve cardiometabolic risk factors (lipid profile, blood pressure, and glycaemic parameters) in adults?
Population
Adults from 45 randomized controlled trials
Comparison
Oral vitamin D supplementation vs Placebo
Design
Meta-analysis
Authors
Loading...
Oral vitamin D supplementation modestly improves cardiometabolic risk factors including LDL-C, systolic blood pressure, fasting blood glucose, and HbA1c in adults.
Meta-Analysis
Does oral vitamin D supplementation improve cardiometabolic risk factors (lipid profile, blood pressure, and glycaemic parameters) in adults?
Mean Difference: -0.136 (95% CI -0.215–-0.056)
Oral vitamin D supplementation modestly improves cardiometabolic risk factors including LDL-C, systolic blood pressure, fasting blood glucose, and HbA1c in adults.
Abumweis et al. (2026) conducted a meta-analysis in Cardiometabolic risk factors. Oral vitamin D supplementation vs. Placebo was evaluated on Low-density lipoprotein cholesterol (LDL-C) (MD -0.136 mmol/L, 95% CI -0.215, -0.056). Vitamin D supplementation significantly reduced LDL-C by 0.136 mmol/L (95% CI: -0.215, -0.056), systolic blood pressure by 2.79 mm Hg, and fasting blood glucose compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: